Table 1.
Description of recipient, donor, and transplantation characteristics of the global study population (qualitative variables).
| Characteristics | Missing data |
N = 1013 |
||
|---|---|---|---|---|
| n | % | n | % | |
| RECIPIENT | ||||
| Male gender | - | - | 631 | 62.3 |
| Rank of the graft ≥ 2 | - | - | 188 | 18.6 |
| Initial nephropathy: Glomerulonephritis | - | - | 273 | 26.9 |
| Pyelonephritis | 471 | 46.5 | ||
| Vascular nephropathy | 107 | 10.6 | ||
| Diabetic nephropathy | 69 | 6.8 | ||
| Other disease and unknown | 93 | 9.2 | ||
| Replacement therapy: Pre-emptive transplantation | - | - | 232 | 22.9 |
| Peritoneal dialysis | 129 | 12.7 | ||
| Hemodialysis | 652 | 64.4 | ||
| DONOR | ||||
| Deceased donor | - | - | 859 | 84.8 |
| ECD | - | - | 428 | 49.8 |
| TREATMENTS | ||||
| Maintenance immunosuppressive by CNI | - | - | 1009 | 99.6 |
| Maintenance immunosuppressive by mTOR inhibitor | - | - | 13 | 1.3 |
| Maintenance immunosuppressive by MMF/MPA/AZA | - | - | 1002 | 98.9 |
| Maintenance immunosuppressive by Corticosteroids | - | - | 867 | 85.6 |
| Induction: No induction | - | - | 15 | 1.5 |
| Non depletant therapy | 511 | 50.4 | ||
| Depletant therapy | 487 | 48.1 | ||
| IMMUNOLOGY | ||||
| Number of HLA-A/B/DR mismatches >4 | - | - | 201 | 19.8 |
| Positive anti-class I HLA antibody | 97 | 9.6 | 294 | 32.1 |
| Positive anti-class II HLA antibody | 107 | 10.6 | 234 | 25.8 |
| Rejection in the first three months post-transplantation | - | - | 53 | 5.2 |
| Rejection after three months post-transplantation (biopsy) | 1 | 0.01 | 75 | 7.4 |
| ABMR | - | - | 29 | 2.9 |
| TCRM | - | - | 29 | 2.9 |
| Borderline | - | - | 16 | 1.6 |
| DSA de novo in the first three months post-transplantation | 27 | 2.7 | 26 | 2.6 |
| DSA de novo after three months post-transplantation | - | - | 98 | 9.7 |